Metropolis Healthcare shows impressive FY26 performance with a 13.7% increase in organic revenue and an EBITDA margin of 25.9%. Aiming for sustained EBITDA margins between 27-28%, the company is focusing on specialty diagnostics, genomics, and productivity enhancements.

Metropolis Healthcare aims to acquire 4-5 companies with reasonable valuations, as per its chairperson Ameera Shah. This strategy is geared towards expanding in the fields of genomics, advanced sequencing, and specialized diagnostics.

Metropolis Healthcare receives a positive outlook from brokerages Nuvama and Emkay following impressive Q4 performance. Both firms have revised their price targets for the company based on its latest results.

Metropolis Healthcare's CEO, C Surendran, discussed their Q4 earnings in a comprehensive interview, outlining key growth drivers for the future. He provided insightful guidance on the company's plans moving forward.

Morgan Stanley maintains a neutral stance on Metropolis Healthcare, suggesting a potential price of INR 564.3, indicating modest growth prospects for the company.

Metropolis Healthcare has announced its Q4 earnings, highlighting significant financial figures for the quarter. These details are now available to investors and stakeholders.

Metropolis Healthcare significantly increased its Q4 EBITDA, reaching ₹1 billion compared to ₹623 million last year, indicating a 60% growth. The company's margin also improved, rising to 25.4%, marking a 7-point increase year over year.

Metropolis Healthcare reported a significant 23% increase in Q4 revenue year-over-year, with EBITDA surging by 31%. This growth was driven both by organic growth at 9.3% and the promising expansion of their TruHealth division.

Metropolis Healthcare aims for a robust 14-15% annual revenue growth rate and expects to maintain a high EBITDA margin of 27-28%. The company's expansion strategy includes establishing around 1,500 new healthcare centers over the next three years.

Metropolis Healthcare announces a dividend of INR 1 per share for FY26, pushing the stock to an intraday high of INR 558.25, while trading around INR 548.1 and recording over INR 82.5 lakh in daily turnover.

Metropolis Healthcare reported a significant 132% jump in Q4 profits, reaching ₹51 crore, with revenue also increasing by 23%. EBITDA rose by 73.4%, and margins improved to 25.4%. Notably, they announced a second interim dividend.

Metropolis Healthcare surged by 9.45% on May 14th, 2026, indicating robust investor optimism. The stock reached an impressive 52-week high of Rs.599.9 during the day's trading.

Metropolis Healthcare reported a 9.3% increase in EPS, moving from 7.43 to 8.12 last year, and revenue jumped by 19% to ₹16 billion. Notably, company insiders own a significant 19% stake, suggesting a strong alignment with shareholder value creation.

Metropolis reached a new 52-week high today, boosted by robust growth in Q4FY26 revenues by 23%. The healthcare sector also saw surges in stocks for Thyrocare, Vijaya, and Dr Lal PathLabs. Notably, Thyrocare led in volume while Vijaya reported record revenue. A positive outlook for Dr Lal PathLabs was also highlighted.

Metropolis Healthcare has broken out of a symmetrical triangle pattern, indicating potential growth as it records higher lows on significantly increased trading volume. The breakout has also pushed the price above its moving average, suggesting positive momentum.

Metropolis Healthcare reported a 23% increase in Q4 revenue, primarily due to strong performance by TruHealth and specialized testing. Both B2C and B2B segments showed growth, with B2C up 19% and B2B up 30%. Organic revenue also increased by 14.5%, while EBITDA margins improved as well.